These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 15507629

  • 1. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.
    Baldwin CE, Sanders RW, Deng Y, Jurriaans S, Lange JM, Lu M, Berkhout B.
    J Virol; 2004 Nov; 78(22):12428-37. PubMed ID: 15507629
    [Abstract] [Full Text] [Related]

  • 2. Second site escape of a T20-dependent HIV-1 variant by a single amino acid change in the CD4 binding region of the envelope glycoprotein.
    Baldwin CE, Berkhout B.
    Retrovirology; 2006 Nov 29; 3():84. PubMed ID: 17134507
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance.
    Chong H, Xu S, Zhang C, Nie J, Wang Y.
    J Clin Virol; 2009 Jul 29; 45(3):255-8. PubMed ID: 19487156
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
    Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW.
    Proc Natl Acad Sci U S A; 2002 Dec 10; 99(25):16249-54. PubMed ID: 12444251
    [Abstract] [Full Text] [Related]

  • 10. C-Terminal gp40 peptide analogs inhibit feline immunodeficiency virus: cell fusion and virus spread.
    Medinas RJ, Lambert DM, Tompkins WA.
    J Virol; 2002 Sep 10; 76(18):9079-86. PubMed ID: 12186891
    [Abstract] [Full Text] [Related]

  • 11. Selection of T1249-resistant human immunodeficiency virus type 1 variants.
    Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, Sanders RW, Berkhout B.
    J Virol; 2008 Jul 10; 82(13):6678-88. PubMed ID: 18434391
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ability of antibodies specific to the HIV-1 envelope glycoprotein to block the fusion inhibitor T20 in a cell-cell fusion assay.
    Vincent N, Malvoisin E.
    Immunobiology; 2012 Oct 10; 217(10):943-50. PubMed ID: 22387075
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F.
    J Virol; 2006 Sep 10; 80(17):8807-19. PubMed ID: 16912327
    [Abstract] [Full Text] [Related]

  • 17. HIV genetic mutations causing resistance to the new drug T-20: recent findings.
    Bean P.
    Am Clin Lab; 2002 Oct 10; 21(8):15-6. PubMed ID: 12440170
    [No Abstract] [Full Text] [Related]

  • 18. Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.
    Chinnadurai R, Rajan D, Münch J, Kirchhoff F.
    J Virol; 2007 Jun 10; 81(12):6563-72. PubMed ID: 17428857
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.